

Virtual Sponsored Symposium to be held in conjunction with the ASTMH 2020 Annual Meeting

Save the Date

Re-starting malaria R&D in the face of COVID in Africa

COVID-19 has put a halt to much of the health research happening worldwide. It is vital that malaria R&D and clinical trials are re-started as soon as possible to ensure we do not lose valuable time bringing much needed innovations, such as new drugs and insecticides, to market.

This symposium will share perspectives from research programmes on how COVID-19 has affected their operations and their planning for re-starting R&D in a safe and effective manner.

Moderator:

• Mark Chataway, Baird's CMC

Speakers:

- **Dr Abdourahmane Diallo**, CEO, RBM Partnership to End Malaria
- Catherine Kyobutungi, Executive Director, African Population and Health Research Centre
- Dr Berhnards Ogutu, Chief Research Officer with the Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist with the Malaria Clinical Trials Alliance of the INDEPTH-Network
- Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)
- Caroline Boulton, Global Programme Head, Malaria, Novartis
- Dr David Reddy, CEO, Medicines for Malaria Venture
- Lacina Koné, Director General, Smart Africa







